Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pBABEpuro-gateway Citations (14)

Originally described in: Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. Epub 2012 Aug 20.
PubMed Journal

Articles Citing pBABEpuro-gateway

CDK1-dependent inhibition of the E3 ubiquitin ligase CRL4CDT2 ensures robust transition from S Phase to Mitosis. Rizzardi LF, Coleman KE, Varma D, Matson JP, Oh S, Cook JG. J Biol Chem. 2015 Jan 2;290(1):556-67. doi: 10.1074/jbc.M114.614701. Epub 2014 Nov 19. PubMed
Expression of the FGFR2 mesenchymal splicing variant in epithelial cells drives epithelial-mesenchymal transition. Ranieri D, Rosato B, Nanni M, Magenta A, Belleudi F, Torrisi MR. Oncotarget. 2016 Feb 2;7(5):5440-60. doi: 10.18632/oncotarget.6706. PubMed
Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. Lovric S, Goncalves S, Gee HY, Oskouian B, Srinivas H, Choi WI, Shril S, Ashraf S, Tan W, Rao J, Airik M, Schapiro D, Braun DA, Sadowski CE, Widmeier E, Jobst-Schwan T, Schmidt JM, Girik V, Capitani G, Suh JH, Lachaussee N, Arrondel C, Patat J, Gribouval O, Furlano M, Boyer O, Schmitt A, Vuiblet V, Hashmi S, Wilcken R, Bernier FP, Innes AM, Parboosingh JS, Lamont RE, Midgley JP, Wright N, Majewski J, Zenker M, Schaefer F, Kuss N, Greil J, Giese T, Schwarz K, Catheline V, Schanze D, Franke I, Sznajer Y, Truant AS, Adams B, Desir J, Biemann R, Pei Y, Ars E, Lloberas N, Madrid A, Dharnidharka VR, Connolly AM, Willing MC, Cooper MA, Lifton RP, Simons M, Riezman H, Antignac C, Saba JD, Hildebrandt F. J Clin Invest. 2017 Mar 1;127(3):912-928. doi: 10.1172/JCI89626. Epub 2017 Feb 6. PubMed
Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Thaler S, Schmidt M, Robetawag S, Thiede G, Schad A, Sleeman JP. Oncotarget. 2017 Aug 14;8(42):72281-72301. doi: 10.18632/oncotarget.20261. eCollection 2017 Sep 22. PubMed
The interactome of EBV LMP1 evaluated by proximity-based BioID approach. Rider MA, Cheerathodi MR, Hurwitz SN, Nkosi D, Howell LA, Tremblay DC, Liu X, Zhu F, Meckes DG Jr. Virology. 2018 Mar;516:55-70. doi: 10.1016/j.virol.2017.12.033. Epub 2018 Jan 9. PubMed
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. Quintanal-Villalonga A, Molina-Pinelo S, Cirauqui C, Ojeda-Marquez L, Marrugal A, Suarez R, Conde E, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L. J Thorac Oncol. 2019 Apr;14(4):641-655. doi: 10.1016/j.jtho.2018.12.021. Epub 2019 Jan 9. PubMed
An unbiased in vitro screen for activating epidermal growth factor receptor mutations. Chakroborty D, Kurppa KJ, Paatero I, Ojala VK, Koivu M, Tamirat MZ, Koivunen JP, Janne PA, Johnson MS, Elo LL, Elenius K. J Biol Chem. 2019 Jun 14;294(24):9377-9389. doi: 10.1074/jbc.RA118.006336. Epub 2019 Apr 5. PubMed
FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Quintanal-Villalonga A, Molina-Pinelo S, Yague P, Marrugal A, Ojeda-Marquez L, Suarez R, Ponce-Aix S, Enguita AB, Carnero A, Ferrer I, Paz-Ares L. Lung Cancer. 2019 May;131:112-121. doi: 10.1016/j.lungcan.2019.02.007. Epub 2019 Feb 8. PubMed
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases. Koivu MKA, Chakroborty D, Tamirat MZ, Johnson MS, Kurppa KJ, Elenius K. Mol Cancer Ther. 2021 Mar;20(3):564-576. doi: 10.1158/1535-7163.MCT-20-0590. Epub 2020 Dec 15. PubMed
Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication. Gowda P, Patrick S, Joshi SD, Kumawat RK, Sen E. Cytokine. 2021 Jun;142:155496. doi: 10.1016/j.cyto.2021.155496. Epub 2021 Mar 12. PubMed
Role of FAM134 paralogues in endoplasmic reticulum remodeling, ER-phagy, and Collagen quality control. Reggio A, Buonomo V, Berkane R, Bhaskara RM, Tellechea M, Peluso I, Polishchuk E, Di Lorenzo G, Cirillo C, Esposito M, Hussain A, Huebner AK, Hubner CA, Settembre C, Hummer G, Grumati P, Stolz A. EMBO Rep. 2021 Sep 6;22(9):e52289. doi: 10.15252/embr.202052289. Epub 2021 Aug 2. PubMed
In Search of Small Molecules That Selectively Inhibit MBOAT4. Murzinski ES, Saha I, Ding H, Strugatsky D, Hollibaugh RA, Liu H, Tontonoz P, Harran PG. Molecules. 2021 Dec 15;26(24). pii: molecules26247599. doi: 10.3390/molecules26247599. PubMed
HiFENS: high-throughput FISH detection of endogenous pre-mRNA splicing isoforms. Shilo A, Pegoraro G, Misteli T. Nucleic Acids Res. 2022 Dec 9;50(22):e130. doi: 10.1093/nar/gkac869. PubMed
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. Chakroborty D, Ojala VK, Knittle AM, Drexler J, Tamirat MZ, Ruzicka R, Bosch K, Woertl J, Schmittner S, Elo LL, Johnson MS, Kurppa KJ, Solca F, Elenius K. Cancer Res Commun. 2022 Jan 7;2(1):10-27. doi: 10.1158/2767-9764.CRC-21-0021. eCollection 2022 Jan. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.